These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35779846)

  • 61. Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
    You R; Mori T; Ke L; Wan Y; Zhang Y; Luo F; Feng D; Yu G; Liu J
    Menopause; 2021 Dec; 29(2):210-218. PubMed ID: 34930866
    [TBL] [Abstract][Full Text] [Related]  

  • 62. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
    Hadji P; Kyvernitakis I; Kann PH; Niedhart C; Hofbauer LC; Schwarz H; Kurth AA; Thomasius F; Schulte M; Intorcia M; Psachoulia E; Schmid T
    Osteoporos Int; 2016 Oct; 27(10):2967-78. PubMed ID: 27172934
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
    Naik-Panvelkar P; Norman S; Elgebaly Z; Elliott J; Pollack A; Thistlethwaite J; Weston C; Seibel MJ
    BMC Fam Pract; 2020 Feb; 21(1):32. PubMed ID: 32050909
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
    Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
    J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Teriparatide and denosumab combination therapy and skeletal metabolism.
    Idolazzi L; Rossini M; Viapiana O; Braga V; Fassio A; Benini C; Kunnathully V; Adami S; Gatti D
    Osteoporos Int; 2016 Nov; 27(11):3301-3307. PubMed ID: 27250971
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Patients' first-year adherence to different anti-osteoporotic therapy after hip fractures.
    Kim SJ; Cho YJ; Lee DW
    Injury; 2021 Jun; 52(6):1506-1510. PubMed ID: 33223260
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Association between pharmacotherapy and secondary hip fracture in a real-world setting: a nationwide database study.
    Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
    J Bone Miner Metab; 2023 Mar; 41(2):248-257. PubMed ID: 36853423
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of teriparatide in osteoporotic fracture patients.
    Collinge C; Favela J
    Injury; 2016 Jan; 47 Suppl 1():S36-8. PubMed ID: 26768289
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.
    Raterman HG; Bultink IEM; Lems WF
    Drugs; 2019 Jul; 79(10):1065-1087. PubMed ID: 31201710
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
    Miyakoshi N; Aizawa T; Sasaki S; Ando S; Maekawa S; Aonuma H; Tsuchie H; Sasaki H; Kasukawa Y; Shimada Y
    J Bone Miner Metab; 2015 Sep; 33(5):553-9. PubMed ID: 25227287
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study.
    Iwata A; Kanayama M; Oha F; Hashimoto T; Iwasaki N
    BMC Musculoskelet Disord; 2017 Apr; 18(1):148. PubMed ID: 28388910
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study.
    Carbonell-Abella C; Pages-Castella A; Javaid MK; Nogues X; Farmer AJ; Cooper C; Diez-Perez A; Prieto-Alhambra D
    Calcif Tissue Int; 2015 Dec; 97(6):535-41. PubMed ID: 26202819
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
    Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
    J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis.
    Miyoshi A; Kameda H; Nagai S; Nakamura A; Miya A; Takase T; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Jul; 12(7):1293-1300. PubMed ID: 33141482
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study.
    Mathieu C; Pambrun E; Bénard-Laribière A; Noize P; Faillie JL; Bezin J; Pariente A
    Eur J Epidemiol; 2022 Oct; 37(10):1049-1059. PubMed ID: 36129659
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Secular trends of use of anti-osteoporotic treatments in Spain: A population-based cohort study including over 1.5million people and more than 12years of follow-up.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Álvarez-Gutiérrez A; Montero-Corominas D
    Bone; 2017 Dec; 105():292-298. PubMed ID: 28890137
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
    Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
    Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Therapy of glucocorticoid induced osteoporosis].
    Arazzi M; Di Fulvio G; Di Pietro LO; Grabocka X; Longo MO; Micioni G; Pezzutto A; Piscitani L; Schiazza A; Silvestri S; Vigilante G; Amoroso L; Bonomini M
    G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.